unanswered questions of interest from the litespark-004 trial
Published 1 year ago • 38 plays • Length 2:32Download video MP4
Download video MP3
Similar videos
-
3:14
the key unanswered question in lung cancer?
-
9:35
litespark-004: 36 month follow-up of belzutifan in von hippel-lindau syndrome
-
2:01
unanswered questions in ph all
-
2:52
litespark-004: esa use in vhl disease-associated rcc
-
22:30
vhl breakthrough: an expert discussion
-
5:06
what is von hippel-lindau disease? one patient's vhl story - the vhl alliance
-
16:26
learn about ocular von hippel-lindau disease with dr. henry wiley
-
2:28
living with von hippel-lindau disease
-
2:09
promising real-world outcomes of belzutifan in vhl-associated tumors
-
1:46
vhl: new drug for genetic disease shrinks tumors
-
1:16
myvhl and samantha greenberg - the vhl alliance
-
14:07
unique characteristics of vhl pancreatic tumors by diagnostic criteria | reut halperin, md, phd
-
30:51
belzutifan trial: phase 2 study to evaluate the efficacy and safety (dr. hendifar) - june 15, 2022
-
3:26
highlights on belzutifan in previously treated advanced clear cell rcc: the litespark-005 study
-
59:03
vhla town hall on welireg
-
13:18
vhl drug therapy | sandy srinivas, md
-
1:42
case 0624 - the lyme mystery
-
4:39
clear cell rcc: vhl/hif pathway
-
1:07
challenges in diagnosis of mesothelioma
-
16:01
lbct 04 novel therapies for common problems
-
1:55
belzutifan real-world vs clinical trial data: comparing efficacy and safety in vhl-associated tumors
-
1:19
von hippel lindau disease